Skip to main content
NewslettersWatchlist

Abbott Laboratories(ABT-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low104.25
Day High108.72
Open:107.53
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript
Baystreet
Abbott Labs Beats Earnings Estimates Due To Medical Device Sales
Barchart
S&P Futures Climb as Investors Shift Focus to Earnings
Barchart
Stocks Set to Open Higher as Iran-Israel Tensions Ease, Earnings and Fed Speak in Focus
Baystreet
Wholesale, Inflation Figures in Canada Due Next Week
Motley Fool
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
Motley Fool
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Motley Fool
3 Top Dividend Stocks to Buy in April 2024
Barchart
3 Passive Income Stocks To Scoop Up Now
Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now.
Newswire.ca
Canadian First - Abbott Advances Chronic Pain Management with the World's Smallest Implanted, Rechargeable Spinal Cord Stimulation System
Barchart
Stocks Settle Lower as Bond Yields Climb on Inflation Concerns
Barchart
Stocks Under Pressure as Bond Yields Climb
Motley Fool
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
Motley Fool
Is Abbott Laboratories a Top Dividend Growth Stock to Buy Now?
Motley Fool
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
Motley Fool
Nearing Retirement? These Stocks Are as Cautious as They Come
Motley Fool
3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade
Motley Fool
Could Abbott Laboratories Stock Help You Become a Millionaire?
Motley Fool
The Smartest Dividend Stocks to Buy With $400 Right Now
Motley Fool
Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How.
Motley Fool
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
Motley Fool
Want to Get Richer? Here Are the 3 Best Stocks to Buy Now and Hold Forever
Motley Fool
2 Stocks to Buy Near Their 52-Week Highs
Motley Fool
2 Healthcare Dividend Kings to Buy and Hold Forever
Motley Fool
Is Abbott Laboratories Stock a Buy Now?
Motley Fool
Could Abbott Labs Be the Next Big Winner in the Billion-Dollar Weight Loss Market?
Barchart
S&P 500 and Nasdaq 100 Post Record Highs on Strong Tech Earnings
Motley Fool
Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript
Barchart
Stocks Climb on Economic Optimism and Strong Tech Earnings
Barchart
Nasdaq Futures Climb as Netflix Results Boost Sentiment, U.S. PMI Data and Tesla Earnings in Focus
Motley Fool
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024

Profile

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.